Format

Send to

Choose Destination
Curr Opin Pharmacol. 2018 Jun;40:67-73. doi: 10.1016/j.coph.2018.03.013. Epub 2018 Apr 3.

Intra-articular drug delivery systems for joint diseases.

Author information

1
Department of Orthopedic Surgery, Musculoskeletal Research Center, Washington University School of Medicine, 660 South Euclid Avenue, Box 8233, Saint Louis, MO 63110, USA; Department of Cell Biology and Physiology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8233, Saint Louis, MO 63110, USA. Electronic address: rai.m@wustl.edu.
2
Department of Medicine, Division of Rheumatology, 660 South Euclid Avenue, Box 8045, Saint Louis, MO 63110, USA. Electronic address: cpham@wustl.edu.

Abstract

Intra-articular (IA) injections directly deliver high concentrations of therapeutics to the joint space and are routinely used in various musculoskeletal conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA). However, current IA-injected drugs are rapidly cleared and do not significantly affect the course of joint disease. In this review, we highlight recent developments in IA therapy, with a special emphasis on current and emerging therapeutic carriers and their potential to deliver disease-modifying treatment modalities for arthritis. Recent IA approaches concentrate on platforms that are safe with efficient tissue penetration, and readily translatable for controlled and sustained delivery of therapeutic agents. Gene therapy delivered by viral or non-viral vectors and cell-based therapy for cartilage preservation and regeneration are being intensively explored.

PMID:
29625332
PMCID:
PMC6015522
DOI:
10.1016/j.coph.2018.03.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center